Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2775240 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY2775240 (Part A) | EXPERIMENTAL | Escalating oral doses of LY2775240 administered in healthy participants |
| LY2775240 (Part B) | EXPERIMENTAL | Oral dose of LY2775240 in healthy participants |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered orally in healthy participants |
| Apremilast (Part B) | ACTIVE_COMPARATOR | Oral dose of apremilast in healthy participants |
| Name | Type | Description |
|---|---|---|
| LY2775240 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
| Apremilast | DRUG | Administered orally |
Inclusion Criteria: * Overtly healthy adult male or a female who cannot get pregnant * Have a screening body mass index (BMI) of greater than 18 and less than or equal to 32 kilograms per meter square (kg/m²), inclusive * Have normal blood pressure, pulse rate, electrocardiogram (ECG) and medical t...
LY2775240 is an investigational small molecule being developed by Eli Lilly and Company. It has been studied in a Phase 1 clinical trial in healthy participants. The specific disease or condition it is intended to treat has not been disclosed.
LY2775240 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The company sponsored the Phase 1 study of the drug in healthy participants.
LY2775240 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA.
LY2775240 has been evaluated in a single Phase 1 trial, NCT02963779, titled A Study of LY2775240 in Healthy Participants. The trial was completed, enrolled 35 participants, and was conducted in Singapore.
The Phase 1 trial NCT02963779 was a randomized, double-blind, placebo-controlled study in healthy participants. It enrolled 35 participants of all sexes, aged 21 years and older, and was conducted in Singapore. The trial has been completed.